Literature DB >> 17256103

Severe limb necrosis: primary thrombotic microangiopathy or "seronegative" catastrophic antiphospholipid syndrome? A diagnostic dilemma.

I Lazurova1, Z Macejova, Z Tomkova, F Remenar, A Boor, J Lazur, R Roland, J Rovensky, R A Asherson.   

Abstract

An episode of gastroenteritis triggered severe necrosis of all extremities in a previously asymptomatic male. Hepatic and renal involvement were also manifest, while the hematological picture was one of thrombotic microangiopathic hemolytic anemia. Antiphospholipid antibodies were negative. He responded well to a combination of plasma exchange, anticoagulation (heparin), parenteral steroids, and antibiotics, as well as vasodilators (prostacycline) and hyperbaric oxygen, but died because of a cerebral hemorrhage. The differential diagnosis included thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome, or seronegative catastrophic antiphospholipid (Asherson's) syndrome. The dangers of administering such a combination of therapies with anticoagulation, as well as vasodilatation (prostacycline) and hyperbaric oxygen, are highlighted by the case report and emphasized.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17256103     DOI: 10.1007/s10067-006-0487-8

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  18 in total

1.  Incidence of the factor V Leiden-mutation, coagulation inhibitor deficiency, and elevated antiphospholipid-antibodies in patients with preeclampsia or HELLP-syndrome. Hemolysis, elevated liver-enzymes, low platelets.

Authors:  G F von Tempelhoff; L Heilmann; E Spanuth; E Kunzmann; G Hommel
Journal:  Thromb Res       Date:  2000-11-15       Impact factor: 3.944

Review 2.  Treatment of thrombotic thrombocytopenic purpura.

Authors:  S Fontana; J A Kremer Hovinga; B Lämmle; B Mansouri Taleghani
Journal:  Vox Sang       Date:  2006-05       Impact factor: 2.144

Review 3.  Multiorgan failure and antiphospholipid antibodies: the catastrophic antiphospholipid (Asherson's) syndrome.

Authors:  Ronald A Asherson
Journal:  Immunobiology       Date:  2005-10-20       Impact factor: 3.144

Review 4.  Insights into von Willebrand factor proteolysis: clinical implications.

Authors:  D J Bowen; P W Collins
Journal:  Br J Haematol       Date:  2006-06       Impact factor: 6.998

Review 5.  Thrombotic thrombocytopenic purpura--then and now.

Authors:  Miriam Galbusera; Marina Noris; Giuseppe Remuzzi
Journal:  Semin Thromb Hemost       Date:  2006-03       Impact factor: 4.180

Review 6.  The molecular biology of thrombotic microangiopathy.

Authors:  H-M Tsai
Journal:  Kidney Int       Date:  2006-05-31       Impact factor: 10.612

7.  Thrombotic thrombocytopenic purpura and sporadic hemolytic-uremic syndrome plasmas induce apoptosis in restricted lineages of human microvascular endothelial cells.

Authors:  D Mitra; E A Jaffe; B Weksler; K A Hajjar; C Soderland; J Laurence
Journal:  Blood       Date:  1997-02-15       Impact factor: 22.113

Review 8.  Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies.

Authors:  G Espinosa; S Bucciarelli; R Cervera; M Lozano; J-C Reverter; G de la Red; V Gil; M Ingelmo; J Font; R A Asherson
Journal:  Ann Rheum Dis       Date:  2004-06       Impact factor: 19.103

9.  Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus.

Authors:  R Cervera; M A Khamashta; J Font; G D Sebastiani; A Gil; P Lavilla; I Doménech; A O Aydintug; A Jedryka-Góral; E de Ramón
Journal:  Medicine (Baltimore)       Date:  1993-03       Impact factor: 1.889

10.  Enhanced endothelial cell apoptosis in splenic tissues of patients with thrombotic thrombocytopenic purpura.

Authors:  C T Dang; M S Magid; B Weksler; A Chadburn; J Laurence
Journal:  Blood       Date:  1999-02-15       Impact factor: 22.113

View more
  3 in total

1.  Complete resolution of a mitral valve vegetation with anticoagulation in seronegative antiphospholipid syndrome.

Authors:  Yuheng Ruan; Jonathan S Bridges; Kapil Kumar; Jonelle A Raphael; Subroto Acharjee; Francine K Welty
Journal:  Clin Rheumatol       Date:  2008-08-21       Impact factor: 2.980

2.  The mosaic of "seronegative" antiphospholipid syndrome.

Authors:  Fabrizio Conti; Antonella Capozzi; Simona Truglia; Emanuela Lococo; Agostina Longo; Roberta Misasi; Cristiano Alessandri; Guido Valesini; Maurizio Sorice
Journal:  J Immunol Res       Date:  2014-03-17       Impact factor: 4.818

3.  "Non-criteria" antiphospholipid antibodies add value to antiphospholipid syndrome diagnoses in a large Chinese cohort.

Authors:  Tingting Liu; Jieyu Gu; Liyan Wan; Qiongyi Hu; Jialin Teng; Honglei Liu; Xiaobing Cheng; Junna Ye; Yutong Su; Yue Sun; Jinfeng Zhou; Gary L Norman; Xuefeng Wang; Chengde Yang; Hui Shi
Journal:  Arthritis Res Ther       Date:  2020-02-21       Impact factor: 5.156

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.